Dr. Coric's background includes leading Biohaven to the successful FDA approval and market launch of Nurtec ODT for migraine treatment ... The company's business model includes partnering with ...

Royalty Pharma senior executives will provide an update on the company’s plans to drive shareholder value creation through leveraging its unique business model ... s Nurtec ODT and Gilead ...

Our #1 AI Stock Pick is on a steep discount - 29.99$ instead of 99.99$! Click here to access exclusive investment research and ad free browsing! Our #1 AI Stock Pick is on a steep discount - 29.99 ...

Newly acquired product Nurtec ODT/Vydura contributed $337 million in ... Zacks Consensus Estimate of $200 million as well as our model estimate of $280 million. Global Vyndaqel family revenues ...

Dr. Coric's background includes leading Biohaven to the successful FDA approval and market launch of Nurtec ODT for migraine treatment ... The company's business model includes partnering with ...

NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Vlad Coric, M.D. to the company’s Board of Directors, effective immediately.

Dr. Coric successfully led Biohaven through the FDA approval and launch of Nurtec ODT for the treatment of migraine. Under his leadership, the company also filed an NDA for its second drug candidate, ...

SAN FRANCISCO/NEW DELHI/SEOUL April 18 (Reuters) - Tesla's long-awaited plans for an affordable car include a U.S-made, stripped-down version of its best-selling electric SUV, the Model Y ...